Kane Biotech Expands Antimicrobial Wound Gel Product Range with New Funding
Kane Biotech Funding Announcement
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech (TSX- V:KNE; OTCQB:KNBIF) has revealed that it is set to receive $200,000 in funding along with advisory services to enhance its antimicrobial product offerings.
Focus on revyve™ Antimicrobial Wound Gel
This funding will support the expansion of the revyve™ antimicrobial wound gel family, which is designed to provide effective wound care solutions. The company plans to allocate resources towards advancing its wound care technology.
Conclusion
Kane Biotech’s initiatives reflect a significant step in enhancing the efficacy of antimicrobial solutions in the healthcare industry. The funding is a testament to the company’s commitment to growth and innovation in wound care.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.